VanEck Associates’s Protalix BioTherapeutics PLX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q4 | – | Sell |
-9,096
| Closed | -$35K | – | 1036 |
|
|
2020
Q3 | $35K | Buy |
9,096
+190
| +2% | +$731 | ﹤0.01% | 965 |
|
|
2020
Q2 | $34K | Buy |
+8,906
| New | +$34K | ﹤0.01% | 935 |
|
|
2019
Q2 | – | Sell |
-7,732
| Closed | -$34K | – | 850 |
|
|
2019
Q1 | $34K | Buy |
7,732
+180
| +2% | +$792 | ﹤0.01% | 805 |
|
|
2018
Q4 | $23K | Buy |
7,552
+1,963
| +35% | +$5.98K | ﹤0.01% | 781 |
|
|
2018
Q3 | $41K | Buy |
5,589
+320
| +6% | +$2.35K | ﹤0.01% | 764 |
|
|
2018
Q2 | $23K | Buy |
5,269
+1,532
| +41% | +$6.69K | ﹤0.01% | 835 |
|
|
2018
Q1 | $20K | Buy |
3,737
+249
| +7% | +$1.33K | ﹤0.01% | 718 |
|
|
2017
Q4 | $23K | Sell |
3,488
-671
| -16% | -$4.43K | ﹤0.01% | 711 |
|
|
2017
Q3 | $24K | Buy |
4,159
+185
| +5% | +$1.07K | ﹤0.01% | 721 |
|
|
2017
Q2 | $33K | Buy |
+3,974
| New | +$33K | ﹤0.01% | 727 |
|
|
2016
Q2 | – | Sell |
-10,682
| Closed | -$90K | – | 883 |
|
|
2016
Q1 | $90K | Buy |
10,682
+61
| +0.6% | +$514 | ﹤0.01% | 684 |
|
|
2015
Q4 | $108K | Buy |
10,621
+3,942
| +59% | +$40.1K | ﹤0.01% | 614 |
|
|
2015
Q3 | $79K | Buy |
6,679
+853
| +15% | +$10.1K | ﹤0.01% | 642 |
|
|
2015
Q2 | $114K | Buy |
+5,826
| New | +$114K | ﹤0.01% | 639 |
|
|
2013
Q4 | – | Sell |
-2,149
| Closed | -$97K | – | 692 |
|
|
2013
Q3 | $97K | Buy |
2,149
+1,141
| +113% | +$51.5K | ﹤0.01% | 604 |
|
|
2013
Q2 | $49K | Buy |
+1,008
| New | +$49K | ﹤0.01% | 626 |
|